José Tadeu Stefano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2499124/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. Metabolic Syndrome and Related Disorders, 2022, ,	1.3	2
2	African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. Annals of Hepatology, 2022, 27, 100728.	1.5	5
3	Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Annals of Hepatology, 2021, 20, 100253.	1.5	21
4	Fatty Pancreas: Disease or Finding?. Clinics, 2021, 76, e2439.	1.5	10
5	O-14 A SYNERGISTIC EFFECT OF PNPLA3 GENE POLYMORPHISM AND INSULIN RESISTANCE INCREASES THE RISK TO NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. Annals of Hepatology, 2021, 24, 100501.	1.5	1
6	Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Clinics, 2021, 76, e2881.	1.5	4
7	Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. Biomedicines, 2021, 9, 1751.	3.2	4
8	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Annals of Hepatology, 2020, 19, 622-626.	1.5	23
9	Aerobic Exercise Training Exerts Beneficial Effects Upon Oxidative Metabolism and Non-Enzymatic Antioxidant Defense in the Liver of Leptin Deficiency Mice. Frontiers in Endocrinology, 2020, 11, 588502.	3.5	11
10	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population. Journal of Hepatology, 2020, 73, S406-S407.	3.7	0
11	<effects aerobic="" and="" exercise="" genes="" in<br="" inflammation="" insulin="" of="" on="" protocol="" related="" resistance="" to="">the Pancreas of ob/ob Mice with NAFLD. Clinical and Experimental Gastroenterology, 2020, Volume 13, 223-234.</effects>	2.3	3
12	HCC in Patients with NAFLD/NASH. , 2020, , 191-203.		0
13	N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. Arquivos De Gastroenterologia, 2019, 56, 184-190.	0.8	18
14	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Annals of Hepatology, 2019, 18, 466-471.	1.5	42
15	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Annals of Hepatology, 2019, 18, 416-421.	1.5	49
16	18F-FDG PET/CT AS AN ASSESSMENT TOOL OF HEPATOCELLULAR CARCINOMA SECONDARY TO NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT IN EXPERIMENTAL MODEL. Arquivos De Gastroenterologia, 2019, 56, 45-50.	0.8	2
17	IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Arquivos De Gastroenterologia, 2019, 56, 431-439.	0.8	15
18	Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH – Proteomic and lipidomic insight. Clinical Nutrition, 2018, 37, 1474-1484.	5.0	66

José Tadeu Stefano

#	Article	lF	CITATIONS
19	Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: AÂprospective pilot study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 369-384.	2.6	96
20	Evolution of Biomarkers of Atherogenic Risk in Liver Transplantation Recipients. Transplantation Proceedings, 2018, 50, 3650-3655.	0.6	6
21	Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 330-335.	1.3	13
22	[18F]FDG PET imaging evaluation on non-alcoholic fatty liver disease and hepatocellular carcinoma model treated with sorafenib. Hepatoma Research, 2018, 4, 35.	1.5	1
23	The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology. Journal of Hepatology, 2017, 66, S166-S167.	3.7	1
24	Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatobiliary Surgery and Nutrition, 2017, 6, 350-352.	1.5	4
25	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 428-432.	1.3	19
26	Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. Menopause, 2016, 23, 876-883.	2.0	44
27	Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 2016, 35, 578-586.	5.0	85
28	Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. World Journal of Hepatology, 2016, 8, 1019.	2.0	2
29	Genetic ancestry analysis in non-alcoholic fatty liver disease patients from Brazil and Portugal. World Journal of Hepatology, 2015, 7, 1433.	2.0	7
30	Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S35-S40.	1.5	22
31	Association of a variant in the regulatory region of NADPH oxidase 4 gene and metabolic syndrome in patients with chronic hepatitis C. European Journal of Medical Research, 2015, 20, 45.	2.2	6
32	Hypocaloric high-protein diet improves clinical and biochemical markers in patients with nonalcoholic fatty liver disease (NAFLD). Nutricion Hospitalaria, 2014, 29, 94-101.	0.3	27
33	Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation. World Journal of Gastroenterology, 2014, 20, 8667.	3.3	13
34	Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study. International Journal of Cardiology, 2013, 164, 221-226.	1.7	73
35	Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCAâ€1â€mediated reverse cholesterol transport. Diabetes/Metabolism Research and Reviews, 2013, 29, 66-76.	4.0	35
36	Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review. Expert Review of Gastroenterology and Hepatology, 2013, 7, 361-364.	3.0	16

José Tadeu Stefano

#	Article	IF	CITATIONS
37	S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Design, Development and Therapy, 2013, 7, 553.	4.3	16
38	Yo Jyo Hen Shi Ko (YHK) Modulates the Expression of Proteins Involved in de novo Lipogenesis and Lipid Exportation in Experimental Nonalcoholic Steatohepatitis (NASH). Journal of Pharmacy and Nutrition Sciences (discontinued), 2013, 3, 48-58.	0.4	0
39	173 CONVENTIONAL AND NOVEL CARDIOVASCULAR RISK FACTORS IN LIVER TRANSPLANT RECIPIENTS (LTR). Journal of Hepatology, 2012, 56, S75-S76.	3.7	216
40	Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 245-251.	3.0	27
41	S-Nitroso-N-acetylcysteine induces de-differentiation of activated hepatic stellate cells and promotes antifibrotic effects in vitro. Nitric Oxide - Biology and Chemistry, 2011, 25, 360-365.	2.7	10
42	Gluco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease. Arquivos De Gastroenterologia, 2011, 48, 186-189.	0.8	34
43	Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?. Liver International, 2011, 31, 377-385.	3.9	16
44	Ischemic Preconditioning-Like Effect of Polyunsaturated Fatty Acid-Rich Diet on Hepatic Ischemia/Reperfusion Injury. Journal of Gastrointestinal Surgery, 2011, 15, 1679-1688.	1.7	9
45	Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis. Obesity Surgery, 2010, 20, 906-912.	2.1	28
46	Association of polymorphisms of glutamate ystein ligase and microsomal triglyceride transfer protein genes in nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 357-361.	2.8	69
47	Combination of <i>N</i> â€acetylcysteine and metformin improves histological steatosis and fibrosis in patients with nonâ€alcoholic steatohepatitis. Hepatology Research, 2008, 38, 159-165.	3.4	93
48	A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. Journal of Hepatology, 2008, 49, 1055-1061.	3.7	91
49	Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice. Biochemical Pharmacology, 2007, 74, 290-297.	4.4	14
50	Nonalcoholic Steatohepatitis (NASH) in OB/OB Mice Treated with Yo Jyo Hen Shi Ko (YHK): Effects on Peroxisome Proliferator-Activated Receptors (PPARs) and Microsomal Triglyceride Transfer Protein (MTP). Digestive Diseases and Sciences, 2007, 52, 3448-3454.	2.3	19
51	Hepatic gene expression profile associated with non-alcoholic steatohepatitis protection by S-nitroso-N-acetylcysteine in ob/ob mice. Journal of Hepatology, 2006, 45, 725-733.	3.7	22
52	Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World Journal of Gastroenterology, 2006, 12, 3821.	3.3	27
53	del 11(q23) as a prognostic factor of iron overload in refractory anemia with ringed sideroblasts. Sao Paulo Medical Journal, 1997, 115, 1513-1515.	0.9	1
54	S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]. Drug Design, Development and Therapy, 0, , 971.	4.3	0